* If you want to update the article please login/register
Patients with H. pylori infection and treated with levofloxacin triple therapy or clarithromycin-based therapy for ten or 14 days were included in this program. Patients were refused if they used antibiotics or proton pump inhibitors within 4 or two weeks, respectively, of the H. pylori eradication confirmation test. Therapy in either group was given for 14 days vs. ten days. Compared to clarithromycin-based therapy, Levofloxacin-based therapy was associated with a higher eradication incidence. The 14-day levofloxacin-based regimen resulted in the highest eradication rate, followed by a 14-day course of clarithromycin. The H. pylori eradication was not affected by diabetes or EGD findings, so no diabetes or EGD findings were influenced by diabetes or EGD findings. Despite diabetes and EGD findings, the findings from this research point to the use of a levofloxacin-based regimen as a first-line therapy in the treatment of H. pylori infection in 14 days.
Source link: https://doi.org/10.1186/s13099-022-00502-3
"Levofloxacin is one of the broad-spectrum antibiotics approved for tuberculosis treatment on second-line. " However, people without a TB diagnosis could also be using levofloxacin as an empirical therapy for patients without a TB report could be used. Patients with TB in a community hospital in Thailand were therefore found to be contaminated with levofloxacin. All patients who were admitted to a community hospital in Nakhon Si Thammarat, Thailand, from 2016 to 2017, were reviewed, including patient medical records. In the hospital, there were a total of 21 patients who received levofloxacin. Following the announcement of TB using the acid-fast bacilli test, ten patients were still receiving levofloxacin-containing regimens. Despite no evidence of drug-resistant TB or negative AFB results in a community hospital in Thailand, the results from this research showed high usage of levofloxacin.
Source link: https://doi.org/10.1155/2022/5647071
"Another fluoroquinolones of Neisseria gonorrhoeae's clinical isolates to newer fluoroquinolones, including levofloxacin in vitro has been reported in Japan. " We investigated the quinolone resistance genes in N. gonorrhoeae isolates from a patient with a clinical failure of levofloxacin therapy. For seven days, a man with gonococcal urethritis was treated with oral 100 mg levofloxacin 3 times a day. The posttreatment isolate's minimum inhibitory concentration was 4-fold higher than that for the pretreatment isolate. We performed DNA sequencing of the quinolone reisistance-determining regions within the gyrA and parC genes to determine quinolone resistance mechanisms in a collection of isolates. Our results show that levofloxacin selects a mutant with an additional modification of the ParC protein gene cording during therapy, which may have increased quinolone resistance in the organism.
Source link: https://doi.org/10.1159/000030344
For about two weeks, C. trachomatis strains were exposed to sub-MIC levofloxacin to determine whether C. trachomatis strains develop resistance under sub-MIC antibacterial exposure in a clinical therapeutic period. And if sub-MIC LVFX is used, resistant strains of C. trachomatis will likely not develop in clinical therapeutic terms, as shown by the following quote.
Source link: https://doi.org/10.1159/000007321
"In the various treatment regimens of Chlamydy trachomatis cervicitis in women, the in vivo efficacy of levofloxacin, one of the most common new quinolone antimicrobial agents, was assessed. " Polymerase chain reaction revealed Cervical C. trachomatis. The eradication rate and the recurrence rate of the different treatment regimens of C. trachomatis were investigated. paraphrase cervicitis caused by LVFX's seven-day treatment is safe and efficient in C. trachomatis uterine cervicitis. ".
Source link: https://doi.org/10.1159/000007270
"The in vitro activity of levofloxacin was tested against 256 clinical strains of four gram-positive genera. " Moreover, 1 of 22 S. agalactiae isolates and 1 of 19 E. faecium isolates was resistant, while 1 of 19 E. faecium isolates was resistant, and 2 of 19 were intermediate. In methicillin-resistant staphylococci and E. faecalis isolates, there were only resistances to levofloxacin in the resistance range. Ofloxacin and ciprofloxacin's MICs were usually 2 to 3 times higher than those of levofloxacin in any case.
Source link: https://doi.org/10.1159/000007234
In immunocompetent CBA/J mice, the minimum inhibitory concentrations of the quinolones are similar. Levofloxacin led to a dose-dependent therapeutic effect and a complete removal of S. pneumoniae from the lungs at 120 mg/kg/day, however ciprofloxacin and ampicillin were hardly useful at all. ".
Source link: https://doi.org/10.1159/000007181
"The in vitro bactericidal effects of therapeutic levofloxacin in clinical isolates of Pseudomonas aeruginosa and Enterococcus faecalis were investigated. " After 10 h of LVFX exposure, an isolate of P. aeruginosa for which the MIC of LVFX was 16 0g/ml was largely eradicated. Despite a similar susceptibility of these organisms to LVFX, it was determined that LVFX has a more potent bactericidal action on P. aeruginosa than on E. faecalis.
Source link: https://doi.org/10.1159/000007133
"Concomitant therapy had no effect on the correlation between LVFX serum and hepatic tissue concentrations, but it dramatically reduced the correlation between the serum and renal tissue concentrations of VCM. " There have been reports that renal dysfunction can be triggered by VCM, and our results have shown that concomitant administration of LVFX and VCM should be treated with caution. ".
Source link: https://doi.org/10.1159/000007113
"Lefloxacin's in vitro performance against 300 Pseudomonas aeruginosa isolated from hospitalized patients, with the exception of those recovering in intensive care or hematology units, was similar to ofloxacin, ciprofloxacin, piperacillin, amikacin, ceftazidime, and imipenem. " Levoloxacin's activity was similar to that of ciprofloxacin, but it was more noticeable than ofloxacin. ".
Source link: https://doi.org/10.1159/000048529
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions